ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Apr 18, 2024
Kinder Morgan Issues Strong Outlook; Adjusts Leverage Target
Image: Kinder Morgan’s shares have been choppy during the past couple years. We liked the 2024 outlook for Kinder Morgan, one of the largest energy infrastructure companies in North America. The company benefits from fee-based cash flows backed by multi-year contracts, and the firm is doing a much better job managing traditional free cash flow and its leverage. In its latest quarterly release, management adjusted lower its long-term leverage target to the range of 3.5x to 4.5x for net-debt-to-Adjusted EBITDA (was 4.5x previously). Shares yield 6.3% on a forward estimated basis.
Apr 18, 2024
Taiwan Semi Puts Up Strong First Quarter, Gives Cautious Outlook
Image: Taiwan Semiconductor’s shares have rallied considerably since the October 2022 bottom. Taiwan Semiconductor put up decent first quarter 2024 results, and its outlook for the second quarter of the year was healthy, albeit not as strong as some investors might have liked. We like its pure-play foundry business, and while there was some cautious commentary on the conference call, we’re sticking with Taiwan Semiconductor as an idea in the ESG Newsletter portfolio.
Apr 17, 2024
ASML Reports First Quarter Results, Reiterates Guidance
Image: ASML Holding is one of our favorite semiconductor ideas. On April 17, ASML Holding reported decent first quarter 2024 results. First quarter net sales came in at €5.29 billion on a gross margin of 51.0%. Net income was €1.22 billion in the quarter. Net bookings in the first quarter of 2024 came in at €3.6 billion, down sequentially from the strong net bookings number delivered in the fourth quarter of 2023. The company continues to be shareholder friendly, paying dividends and buying back €400 million worth of stock during the first quarter. Though management expects 2024 total net sales to be similar to 2023, we like how ASML is positioned for the long run.
Apr 16, 2024
Johnson & Johnson Narrows 2024 Outlook, Raises Dividend
Image Source: J&J. Looking to 2024, J&J expects adjusted operational sales growth in the range of 5.5%-6%, the midpoint of which is up from the prior range of 5%-6%. Adjusted operational diluted earnings per share is targeted in the range of $10.60-$10.75 per share, the midpoint also up from the range of $10.55-$10.75 previously. Management also upped its dividend 4.2%, to a quarterly payout of $1.24 per share, implying a forward estimated dividend yield of 3.4%. We like J&J, but we won’t be adding it back to any newsletter portfolio anytime soon.
Apr 16, 2024
UnitedHealth Group Reiterates 2024 Adjusted Net Earnings Outlook
Image: UnitedHealth Group’s shares have been choppy during the past couple years. UnitedHealth Group’s shares have seen better days as the firm works to recover from a cyberattack, while the industry’s medical costs are on the rise as patients begin to pursue procedures that were deferred during the peak of the COVID-19 crisis. Though it may be some time for UnitedHealth Group’s performance to normalize given the cyberattack and pent-up demand, we liked that it maintained its adjusted net earnings outlook for 2024 amid concerns of rising costs. UnitedHealth remains a key idea in the Best Ideas Newsletter portfolio.
Apr 15, 2024
Goldman Sachs Delivers in First Quarter
Image Source: Goldman Sachs. Goldman Sachs put up solid first-quarter 2024 results across all lines of its business, revealing that capital markets activity remains very healthy, even in the face of elevated interest rates. Goldman Sachs' book value per share was $321.10 at the end of the first quarter, revealing that shares are trading at 1.25x book at the time of this writing.
Apr 13, 2024
Vertex Pharma to Acquire Alpine Immune Services
Image: Vertex Pharma’s shares have had a nice run the past couple years. On April 10, Vertex Pharma announced that it had entered into an agreement where Vertex will acquire Alpine Immune Services for $65 per share or ~$4.9 billion in cash. We have no qualms with the deal for Alpine, and we expect Vertex Pharma to continue to deliver for shareholders.
Apr 12, 2024
JPMorgan Cautious on Geopolitical Tensions and Inflationary Pressures
Image Source: Hakan Dahlstrom. On April 12, JPMorgan reported mixed first-quarter 2024 results. JPMorgan is one of our favorite banks, in part due to strong leadership at the top and solid fortress-like balance sheet. Though we don’t include any individual bank in the newsletter portfolios, we do think the Financial Select Sector SPDR makes sense for diversification reasons, as showcased in the Best Ideas Newsletter portfolio. Shares of JPMorgan yield ~2.4% at the time of this writing.
Apr 12, 2024
Dividend Increases/Decreases for the Week of April 12
Let's take a look at firms raising/lowering their dividends this week.
Apr 11, 2024
Fastenal Puts Up Mixed First Quarter Results
Image: Fastenal reported mixed first quarter 2024 results. We like its business model quite a bit. On April 11, Fastenal Company reported mixed first-quarter fiscal 2024 results with revenue and earnings per share coming in slightly lower than expectations. Net sales advanced 1.9% for the three-month period ending March 31. The company noted that adverse weather impacted sales in its first quarter by about 10 to 30 basis points on a net basis. Operating income nudged lower in the quarter modestly, while net income advanced 0.9% in the period on a year-over-year basis. Diluted earnings per share was roughly flat in the quarter on a year-over-year basis, increasing 0.6% from the same period a year ago. We like Fastenal’s business model quite a bit, and shares yield ~2.1% at the time of this writing.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.